Compare RNA & UMBF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNA | UMBF |
|---|---|---|
| Founded | 2012 | 1913 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.6M | 9.4B |
| IPO Year | 2025 | 2006 |
| Metric | RNA | UMBF |
|---|---|---|
| Price | $13.58 | $109.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 10 |
| Target Price | $69.26 | ★ $140.20 |
| AVG Volume (30 Days) | ★ 857.9K | 470.4K |
| Earning Date | 01-01-0001 | 04-28-2026 |
| Dividend Yield | N/A | ★ 1.58% |
| EPS Growth | N/A | ★ 3.34 |
| EPS | N/A | ★ 9.29 |
| Revenue | N/A | N/A |
| Revenue This Year | $88.12 | $18.03 |
| Revenue Next Year | $18.11 | $6.55 |
| P/E Ratio | ★ N/A | $11.73 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.95 | $82.00 |
| 52 Week High | $73.06 | $136.11 |
| Indicator | RNA | UMBF |
|---|---|---|
| Relative Strength Index (RSI) | 11.09 | 36.59 |
| Support Level | $13.06 | $105.42 |
| Resistance Level | $72.75 | $113.20 |
| Average True Range (ATR) | 0.63 | 2.67 |
| MACD | 2.01 | 0.29 |
| Stochastic Oscillator | 46.19 | 34.86 |
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
UMB Financial Corp, or UMBF, is a financial services holding company offering a suite of banking services and asset servicing to its customers in the United States and around the world. Its client base includes commercial, institutional, and personal customers. Along with its subsidiaries, the company operates in the following business segments: Commercial Banking, Institutional Banking, and Personal Banking. A majority of its revenue is generated from the Commercial Banking segment, which serves the commercial banking and treasury management needs of small to middle-market businesses through various products and services such as commercial loans, commercial real estate financing, commercial credit cards, letters of credit, loan syndication services, consultative services, and others.